NASDAQ: CAPR - Capricor Therapeutics, Inc.

六个月盈利: +198.31%
股息率: 0.00%
部门: Healthcare

促销时间表 Capricor Therapeutics, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).

更多详情
It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2007-02-13
ISIN US14070B3096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.capricor.com
Цена ао 4.19
每日价格变化: 0% (14.08)
每周价格变化: +7.73% (13.07)
每月价格变化: -26.05% (19.04)
3个月内价格变化: +41.51% (9.95)
六个月内的价格变化: +198.31% (4.72)
每年价格变化: +187.93% (4.89)
3年内价格变化: +335.91% (3.23)
5年内价格变化: +665.22% (1.84)
10年价格变化: 0% (14.08)
年初以来价格变化: -23.69% (18.45)
所有参数

低估

姓名 意义 年级
P/S 4.73 3
P/BV 5.27 2
P/E 0 0
EV/EBITDA -4.78 0
全部的: 4.38

效率

姓名 意义 年级
ROA, % -37.95 0
ROE, % -98.61 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.2439 10
全部的: 9.6

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 2417.81 10
盈利能力 Ebitda, % 194.99 10
盈利能力 EPS, % -58.18 0
全部的: 8
更多详情

机构 体积 分享, %
Vanguard Group Inc 1165404 3.7
Woodline Partners LP 909542 2.89
Blackrock Inc. 359673 1.14
Geode Capital Management, LLC 316198 1
Susquehanna International Group, LLP 149115 0.47
Renaissance Technologies, LLC 146321 0.46
Northern Trust Corporation 127229 0.4
Osaic Holdings Inc 116550 0.37
State Street Corporation 85224 0.27
Bank Of New York Mellon Corporation 84759 0.27

ETF 分享, % 本年盈利能力, % 股息, %
iShares Neuroscience and Healthcare ETF 0.2793 19.72 0.03
iShares Micro-Cap ETF 0.03249 17.09 1.54048
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
iShares Russell 2000 Growth ETF 0.00807 38.04 0.6026
ProShares UltraPro Russell2000 0.00277 89.82 1.47873
ProShares Hedge Replication ETF 0.0008 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



导师 职称 支付 出生年份
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 120k 1956 (69 年)
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 280.62k 1963 (62 年)
Mr. Anthony J. Bergmann M.B.A. CFO & Corporate Treasurer 437k 1986 (39 年)
Ms. Karen G. Krasney Executive VP, General Counsel & Secretary 426.72k 1953 (72 年)
Dr. Kristi A. H. Elliott Ph.D. Chief Science Officer N/A
Catherine Lee Kelleher Consultant N/A

地址: United States, San Diego. CA, 10865 Road to the Cure - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.capricor.com